<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012974</url>
  </required_header>
  <id_info>
    <org_study_id>CHI 99-063</org_study_id>
    <nct_id>NCT00012974</nct_id>
  </id_info>
  <brief_title>Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas</brief_title>
  <official_title>Innovative Strategies for Implementing New CHF Guideline Recommendations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of telephone-administered
      cognitive-behavioral therapy (T-CBT) in treating major depression among veterans served by
      community-based outpatient clinics (CBOCs) in the Veteran�s Integrated Service Network (VISN)
      21, which serves rural areas in Northern California
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More that 20% of patients in primary care have depressive disorders. While primary care is
      the principal venue for treatment for depression, fewer than 25% of depressed patients
      receive adequate treatment for their depression. These outcomes can be worse when there are
      barriers to treatment such as living in a rural area. Several studies have found that given a
      choice, about two-thirds of depressed primary care patients prefer psychotherapy or
      counseling over antidepressant medication.

      This is a controlled, randomized trial in which subjects meeting criteria for major
      depressive disorder (MDD) from primary care settings in VISN 21 including CBOCs will be
      randomly assigned to one of two conditions: 1) a 16-session manualized telephone administered
      cognitive behavioral therapy (T-CBT) delivered over 24 weeks or 2) a treatment-as-usual (TAU)
      condition. Telephone-administered cognitive behavioral therapy (T-CBT) is an intervention
      aimed at improving coping skills and social functioning. It is divided into two phases: 1) an
      initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of
      depression, and 2) a booster phase in which 4 sessions are provided at increasingly greater
      intervals to target maintenance of treatment gains. T-CBT, administered by doctoral level
      psychologists, will be compared to a treatment-as-usual (TAU) condition that controls for the
      natural course of depression during the course of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in severity of depression; scores on depression rating scales at baseline, 12 weeks and 24 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of treatment gains at 6 month follow-up (week 48).</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <condition>Beta-blocker Treatment</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Provider education, computer reminders, nurse case management</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must have chronic heart failure, systolic left ventricular dysfunction (ejection
        fraction less than or equal to 45%), not be receiving beta-blockers, and not have
        contraindications to beta-blockers.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry M Massie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco VA Medical Center, San Francisco, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Northern California Health Care System, Mather, CA</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Massie BM. Comment--LVADs as long-term cardiac replacement: Success but on what terms and at what cost? J Card Fail. 2002 Apr;8(2):61-2.</citation>
    <PMID>12016627</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;287(12):1541-7.</citation>
    <PMID>11911756</PMID>
  </results_reference>
  <results_reference>
    <citation>Leier CV, Silver MA, Massie BM, Young JB, Fowler MB, Ventura HO, Hershberger RE. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 1--the medical history. Congest Heart Fail. 2001 Sep-Oct;7(5):245-249.</citation>
    <PMID>11832662</PMID>
  </results_reference>
  <results_reference>
    <citation>Dauterman KW, Go AS, Rowell R, Gebretsadik T, Gettner S, Massie BM. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001 Sep;7(3):221-8.</citation>
    <PMID>11561221</PMID>
  </results_reference>
  <results_reference>
    <citation>Go AS, Rao RK, Dauterman KW, Massie BM. A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States. Am J Med. 2000 Feb 15;108(3):216-26.</citation>
    <PMID>10723976</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O'Connor CM, Pina I, Quigg R, Silver M, Robinson LA, Leimberger JD, Gheorghiade M. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J. 2000 Jan;139(1 Pt 1):15-22.</citation>
    <PMID>10618557</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM. Obesity and heart failure--risk factor or mechanism? N Engl J Med. 2002 Aug 1;347(5):358-9.</citation>
    <PMID>12151474</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Rydén L. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med. 2001 Jan 22;161(2):165-71.</citation>
    <PMID>11176729</PMID>
  </results_reference>
  <results_reference>
    <citation>Ashton CM, Bozkurt B, Colucci WB, Kiefe CI, Mann DL, Massie BM, Slawsky MT, Tierney WM, West JA, Whellan DJ, Wray NP. Veterans Affairs Quality Enhancement Research Initiative in chronic heart failure. Med Care. 2000 Jun;38(6 Suppl 1):I26-37. Review.</citation>
    <PMID>10843268</PMID>
  </results_reference>
  <results_reference>
    <citation>Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002 Jun;8(3):136-41.</citation>
    <PMID>12140805</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM. Treating heart failure: it's time for new paradigms and novel approaches. J Card Fail. 2002 Jun;8(3):117-9.</citation>
    <PMID>12140801</PMID>
  </results_reference>
  <results_reference>
    <citation>Ansari M, Tutar A, Bullard J, Teerlink J, Massie B. Cardiology specialist care of heart failure patients improves survival. [Abstract]. Journal of the American College of Cardiology. 2001 Jun 1; 37:189A.</citation>
  </results_reference>
  <results_reference>
    <citation>Massie BM. Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?. J Am Coll Cardiol. 2002 Jan 2;39(1):79-82.</citation>
    <PMID>11755290</PMID>
  </results_reference>
  <results_reference>
    <citation>Ansari M, Tutar A, Bullard J, Teerlink J, Massie B. Heart failure in a veteran cohort: Predictors of outcome. [Abstract]. Journal of the American College of Cardiology. 2001 Jun 1; 37:1581.</citation>
  </results_reference>
  <results_reference>
    <citation>Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000 Sep 25;160(17):2645-50.</citation>
    <PMID>10999979</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM. The year in heart failure: 2004. J Card Fail. 2005 Feb;11(1):1-6. Erratum in: J Card Fail. 2005 Apr;11(3):246.</citation>
    <PMID>15704055</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM. Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients. ACP J Club. 2005 Mar-Apr;142(2):37.</citation>
    <PMID>15739984</PMID>
  </results_reference>
  <results_reference>
    <citation>Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor's new clothes? Circulation. 2005 Mar 29;111(12):1459-61.</citation>
    <PMID>15795361</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM. Heart failure trials: are they becoming impractical? J Card Fail. 2005 Apr;11(3):161-3.</citation>
    <PMID>15812741</PMID>
  </results_reference>
  <verification_date>December 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2001</study_first_submitted>
  <study_first_submitted_qc>March 15, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2001</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

